Current Therapies in Kidney Transplant Rejection

Area of Science:

• Nephrology
• Transplantation Immunology

Background:

• Kidney transplant rejection poses a significant threat to graft survival despite advancements in immunosuppression.
• Acute T-cell-mediated rejection (TCMR) and antibody-mediated rejection (ABMR) are major causes of graft dysfunction.

Purpose of the Study:

• To provide an overview of the diagnosis, current therapies, and management strategies for TCMR and ABMR.
• To highlight the limitations of existing treatments and the need for further research.

Main Methods:

• Review of diagnostic criteria for TCMR and ABMR, focusing on kidney biopsy findings.
• Analysis of current therapeutic approaches, including corticosteroids, T-cell-depleting agents, plasmapheresis, and other immunomodulatory drugs.
• Discussion of management strategies based on rejection type and clinical presentation.

Main Results:

• TCMR diagnosis relies on histological evidence of mononuclear cell infiltration.
• Corticosteroids are first-line for TCMR; T-cell-depleting agents are used for severe cases.
• ABMR treatment involves plasmapheresis, with variable efficacy; other therapies like IVIg and anti-CD20 antibodies are also used.
• Efficacy of current ABMR treatments remains questionable, necessitating careful management decisions.

Conclusions:

• Optimizing immunosuppression and patient adherence are crucial for managing both TCMR and ABMR.
• Existing therapies for ABMR have limitations, and their efficacy is debated.
• Further research into novel therapeutics and rigorous evaluation of their effectiveness are essential for improving long-term kidney transplant outcomes.